Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AEM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Applied and Environmental Microbiology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AEM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Microbial Ecology

Low Relative Abundances of the Mucolytic Bacterium Akkermansia muciniphila and Bifidobacterium spp. in Feces of Children with Autism

Lv Wang, Claus T. Christophersen, Michael J. Sorich, Jacobus P. Gerber, Manya T. Angley, Michael A. Conlon
Lv Wang
1Sansom Institute for Health Research, University of South Australia, Adelaide, South Australia 5001, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claus T. Christophersen
2Preventative Health National Research Flagship, CSIRO Food and Nutritional Sciences, Adelaide, South Australia 5001, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Sorich
1Sansom Institute for Health Research, University of South Australia, Adelaide, South Australia 5001, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacobus P. Gerber
1Sansom Institute for Health Research, University of South Australia, Adelaide, South Australia 5001, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manya T. Angley
1Sansom Institute for Health Research, University of South Australia, Adelaide, South Australia 5001, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: manya.angley@unisa.edu.au
Michael A. Conlon
2Preventative Health National Research Flagship, CSIRO Food and Nutritional Sciences, Adelaide, South Australia 5001, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AEM.05212-11
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Gastrointestinal disturbance is frequently reported for individuals with autism. We used quantitative real-time PCR analysis to quantify fecal bacteria that could influence gastrointestinal health in children with and without autism. Lower relative abundances of Bifidobacteria species and the mucolytic bacterium Akkermansia muciniphila were found in children with autism, the latter suggesting mucus barrier changes.

TEXT

Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder where gastrointestinal (GI) disturbance is commonly reported (11). Evidence is emerging that the profiles of the GI microbiota (8, 9, 16, 22) and fermentation products (2, 28) in individuals with ASD are different from those of the general population. Finegold et al. (9) have reported a relationship between regressive autism and altered GI microbiota. Indeed, the modulation of intestinal microbiota in children with ASD through the use of antibiotics (19) and probiotics such as Lactobacillus plantarum WCSF1 (17) has been shown to improve behavior and bowel health outcomes. In this study, various GI bacteria, including Clostridium spp., members of the Bacteroides fragilis group, Akkermansia muciniphila, and Prevotella species, which are emerging as important markers of GI health, were examined in children with ASD, their siblings, and community controls. We also investigated whether correlations exist between GI microbial abundances and the presence or absence of caregiver-reported functional GI disorders (FGIDs) in children with ASD.

The inclusion criteria for participants were as previously described (26). Briefly, fecal samples were collected from children with ASD (n = 23), recruited through Autism SA, who were diagnosed by a multidisciplinary team using the childhood autism rating scale (20) and/or the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (3). The ASD participants were diagnosed with autistic disorder (n = 17) and Asperger's syndrome (n = 6), and all but three participants were reported to have a regressive form of autism. Children who met the criteria for ASD but presented with a comorbid diagnosis of a chromosomal abnormality were excluded from the study. We also recruited 22 typically developing siblings (SIB) of the ASD cohort as well as 9 unrelated community controls (CON) without a family history of autism as two different control groups. The CON participants were eligible to participate if they did not have a sibling or first cousin with ASD. Participants' caregivers were required to complete a functional gastrointestinal disorder (FGID) questionnaire (21) and a questionnaire that investigated medication use.

Fresh fecal specimens were collected from participants over a 48-h period to exclude day-to-day variability. Each bowel movement was collected in a separate bag and frozen immediately in a portable freezer and stored at −20°C. Specimens were transported to the laboratory in freezers and stored at −80°C until they were processed. Specimens were defrosted at room temperature, and all processing was performed under anaerobic conditions (Bactron IV anaerobic chamber; Sheldon). The mass of each stool sample was recorded prior to being combined with individual participants' other stool samples collected in the 48-h sampling period. Fecal samples were homogenized, and fecal aliquots were taken for DNA extraction and analysis.

DNA was extracted from 0.25 g fecal matter using a repeat bead beating plus column method (29). The primers and optimized quantitative real-time PCR (qPCR) conditions used are summarized in Table S1 in the supplemental material. All qPCR analysis was performed on a CFX 384TM real-time PCR detection system (Bio-Rad, Hercules, CA) in triplicate and a total volume of 10 μl. Each reaction mixture consisted of 4 μl (1 ng/μl) DNA template and 6 μl PCR mixture containing 5 μl SsoFast EvaGreen Supermix, 0.5 μl bovine serum albumin, forward and reverse primers, and PCR-grade water (Sigma-Aldrich, St. Louis, MO). The qPCR cycling conditions were as follows: hot start at 98°C for 3 min, followed by 35 cycles of two-step qPCR with denaturing at 98°C for 15 s, using the annealing/elongation times and temperatures shown in Table S1 in the supplemental material. This was followed by fluorescence acquisition after each cycle. A final melt curve analysis was performed after completion of all cycles, with fluorescence acquired at 0.5°C intervals between 55 and 95°C to verify specificity of amplification. A series of eight 10-fold dilutions of a plasmid construct containing the target amplicon were analyzed in parallel with DNA samples for estimation of absolute abundance and PCR efficiency. Data were analyzed with Bio-Rad CFX Manager software (version 1.5) for absolute quantities (see Table S2 in the supplemental material). Relative abundances of bacterial groups were analyzed with qbase+ (Biogazelle, Ghent, Belgium) (10, 23). Data were normalized by log10 transformation before statistical analyses were conducted, using SPSS for Windows (version 17; SPSS Inc., Chicago, IL). A P value of less than 0.05 was considered statistically significant.

Analysis of participants' characteristics showed a higher incidence of FGIDs in children with ASD than in CON participants, whereas the incidence of FGIDs in the SIB participants was intermediate between the ASD and CON participants (Table 1). Of the 23 children with ASD, nine had GI problems, and of those, four had both constipation and diarrhea, four had constipation only, and one had diarrhea only. Of the siblings, one had both constipation and diarrhea, one had diarrhea only, and four had constipation only. One of the children in the community control group was experiencing constipation.

View this table:
  • View inline
  • View popup
Table 1.

Characteristics of participantsa

A lower relative abundance of Bifidobacterium spp. in ASD participants than in CON (P = 0.006) and SIB (P = 0.032) participants was observed. Abundance of A. muciniphila was decreased in ASD participants relative to that in CON participants (P = 0.029) and decreased in SIB participants relative to that in CON participants (P = 0.031). Moreover, there were elevated relative numbers of the B. fragilis group in ASD children experiencing FGIDs compared to those without FGIDs (P = 0.019). No other bacterial targets differed in abundance between study groups (Table 2).

View this table:
  • View inline
  • View popup
Table 2.

Relative abundances of target bacteriaa

The lower relative abundance of Bifidobacterium spp. in ASD participants relative to controls (SIB and CON) in our study is consistent with the recent findings of Adams et al. (1). In contrast, another study reported similar levels of Bifidobacterium spp. in children with and without ASD (16). ASD participants in the latter study had taken several courses of antibiotics (90%) and/or probiotics (53%) prior to entering the study, which may have influenced composition of the GI microbiota. Notably, only one of our ASD participants received antibiotics during the week prior to the sampling period. Furthermore, none of the SIB or CON participants received antibiotics immediately prior to or during the sampling period. In addition, two of our ASD participants were taking probiotics during the sample collection period. Further investigation of the relationship between Bifidobacterium spp., antibiotics, probiotics, and ASD is warranted. Using the correct species of Bifidobacterium spp. will be important; e.g., Bifidobacterium longum Ncc3001 has been shown to improve anxiety in mice via the vagal nerve (15).

A. muciniphila is a mucin-degrading bacterium present in abundance in the guts of healthy adults, but numbers are reduced in patients with Crohn's disease or ulcerative colitis and in the elderly (4, 14, 18). This indicates that A. muciniphila could be an important marker for gut health. A thinner mucus layer is often present in patients with ulcerative colitis than in controls (5), which probably represents less substrate for mucin-degrading bacteria and hence lower numbers in the feces. Therefore, our finding of a lower abundance of A. muciniphila in ASD children and their siblings may indicate a thinner GI mucus barrier in ASD children than in the CON participants. These results could represent indirect evidence of impaired gut permeability in children with ASD (6, 7). A previous study (6) has indicated that there may be increased gut permeability in ASD children and their first-degree relatives. Our finding of decreases in A. muciniphila in both ASD children and their siblings could support this hypothesis. Although we have suggested that a lower relative abundance of A. muciniphila may represent altered mucus turnover, we have insufficient knowledge to determine if this actually represents a beneficial or detrimental difference. Other bacteria not measured in this study can also degrade mucus and could also potentially contribute to altered mucus barrier function and/or perturb levels of A. muciniphila. Hence, analysis of numbers of a wider range of mucus-degrading bacteria in feces of children with ASD in future studies would be informative.

Species within the B. fragilis group have beneficial effects on host health, while others cause infections with significant morbidity and mortality (27). As higher numbers of the B. fragilis group were found in ASD children with reported FGIDs, it is possible that some species belonging to the B. fragilis group are responsible for GI pathology in children with autism. Future analyses that target specific members of the B. fragilis group will shed further light on the species involved.

In contrast to results from previous studies (16, 22), in this study similar levels of bacteria from Clostridium cluster I were found in all participants. A higher abundance of members of the Clostridium histolyticum group (Clostridium cluster I plus cluster II) was reported in children with ASD by Parracho et al. (16). However, most participants (76%) in their study had diarrhea, and 66% of participants were implementing gluten-free and/or casein-free diets. Also, the results of Parracho et al. were based on a single fecal sample from each participant. We collected samples over a period of 48 h, which provides a better representation of the GI microbial population and eliminates diurnal variations. The most common FGID symptom in ASD in our cohort was constipation, and only four children were implementing a gluten-free and/or casein-free diet. The study by Song et al. (22) showed significantly higher numbers of Clostridium cluster I and Clostridium bolteae bacteria in fecal specimens of children with ASD than that in controls, but they provided only limited information regarding participants or sample collection methodology, both of which are needed to understand points of difference with the current study. Thus, the different findings regarding the abundance of Clostridium species may relate to diverse presentation of FGIDs and various dietary interventions in the study cohorts. In addition, numbers of targeted bacteria such as Faecalibacterium prausnitzii, members of the Clostridium leptum group, and members of the Clostridium coccoides group, which cover many of the primary butyrate producers and are beneficial for gut health, did not significantly differ among the study groups.

Previous studies in rats by MacFabe et al. have shown that intraventricular administration of propionate induces behaviors resembling autism (e.g., repetitive dystonic behaviors, retropulsion, seizures, and social avoidance) (12, 13). We have also reported increased fecal propionate concentrations in ASD children compared with that in controls in the same fecal samples (25). However, the abundance of a key propionate-producing bacterium, Prevotella sp., was not significantly different between the study groups. This suggests that other untargeted bacteria, such as those from Clostridium cluster IX, which also includes major propionate producers (24), may be responsible for the observed differences in fecal propionate concentrations. Moreover, it is possible that the activities of the bacteria responsible for producing propionate, rather than bacterial numbers, have been altered. Other factors, such as differences in GI function that change GI transit time in ASD children, should also be considered.

In summary, the current findings of depleted populations of A. muciniphila and Bifidobacterium spp. add to our knowledge of the changes in the GI tracts of ASD children. These findings could potentially guide implementation of dietary/probiotic interventions that impact the gut microbiota and improve GI health in individuals with ASD.

ACKNOWLEDGMENTS

This research was funded by The Australian Rotary Health Research Fund.

We express our gratitude to the participating children and their parents. We also acknowledge Richard Couper, pediatric gastroenterologist, for medical advice; Rosalind Miller for statistical analysis assistance; as well as Corinna Bennett, Emma Watson, and Kerry Nyland for technical assistance.

FOOTNOTES

    • Received 6 May 2011.
    • Accepted 12 July 2011.
    • Accepted manuscript posted online 22 July 2011.
  • ↵† Supplemental material for this article may be found at http://dx.doi.org/10.1128/AEM.05212-11.

  • Copyright © 2011, American Society for Microbiology. All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Adams J. B.,
    2. Johansen L. J.,
    3. Powell L. D.,
    4. Quig D.,
    5. Rubin R. A.
    . 2011. Gastrointestinal flora and gastrointestinal status in children with autism—comparisons to typical children and correlation with autism severity. BMC Gastroenterol. 11: 22.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Altieri L.,
    2. et al
    . 2011. Urinary p-cresol is elevated in small children with severe autism spectrum disorder. Biomarkers 16: 252–260.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders, 4th ed. American Psychiatric Press, Washington, DC.
  4. 4.↵
    1. Collado C.,
    2. Derrien M.,
    3. Isolauri E.,
    4. de Vos W. M.,
    5. Salminen S.
    . 2007. Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly. Appl. Environ. Microbiol. 73: 7767–7770.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Corazziari E. S.
    2009. Intestinal mucus barrier in normal and inflamed colon. J. Pediatr. Gastroenterol. Nutr. 48: S54–S55.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. de Magistris L.,
    2. et al
    . 2010. Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. J. Pediatr. Gastr. Nutr. 51: 418–424.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. D'Eufemia P.,
    2. et al
    . 1996. Abnormal intestinal permeability in children with autism. Acta Paediatr. 85: 1076–1079.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Finegold S. M.,
    2. et al
    . 2010. Pyrosequencing study of fecal microflora of autistic and control children. Anaerobe 16: 444–453.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Finegold S. M.,
    2. et al
    . 2002. Gastrointestinal microflora studies in late-onset autism. Clin. Infect. Dis. 35: S6–S16.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Hellemans J.,
    2. Mortier G.,
    3. De Paepe A.,
    4. Speleman F.,
    5. Vandesompele J.
    . 2007. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol. 8: R19.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Horvath K.,
    2. Papadimitriou J. C.,
    3. Rabsztyn A.,
    4. Drachenberg C.,
    5. Tyson Tildon J.
    . 1999. Gastrointestinal abnormalities in children with autistic disorder. J. Pediatr. 135: 559–563.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. MacFabe D. F.,
    2. et al
    . 2007. Neurobiological effects of intraventricular propionic acid in rats: possible role of short chain fatty acids on the pathogenesis and characteristics of autism spectrum disorders. Behav. Brain Res. 176: 149–169.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. MacFabe D. F.,
    2. et al
    . 2008. A novel rodent model of autism: intraventricular infusions of propionic acid increase locomotor activity and induce neuroinflammation and oxidative stress in discrete regions of adult rat brain. Am. J. Biochem. Biotechnol. 4: 146–166.
    OpenUrlCrossRef
  14. 14.↵
    1. Miller R. S.,
    2. Hoskins L. C.
    . 1981. Mucin degradation in human colon ecosystems. Fecal population densities of mucin-degrading bacteria estimated by a “most probable number” method. Gastroenterology 81: 759–765.
    OpenUrlPubMedWeb of Science
  15. 15.↵
    1. Park A. J.,
    2. et al
    . 2011. The anxiolytic effect of Bifidobacterium longum Ncc3001 requires vagal integrity for gut-brain communication. Gastroenterology 140: S18–S19.
    OpenUrl
  16. 16.↵
    1. Parracho H. M.,
    2. Bingham M. O.,
    3. Gibson G. R.,
    4. McCartney A. L.
    . 2005. Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. J. Med. Microbiol. 54: 987–991.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Parracho H. M. R. T.,
    2. et al
    . 2010. A double-blind, placebo-controlled, crossover-designed probiotic feeding study in children diagnosed with autistic spectrum disorders. Int. J. Probiotics Prebiotics 5: 69–74.
    OpenUrl
  18. 18.↵
    1. Png C. W.,
    2. et al
    . 2010. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am. J. Gastroenterol. 105: 2420–2428.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Sandler R. H.,
    2. et al
    . 2000. Short-term benefit from oral vancomycin treatment of regressive-onset autism. J. Child Neurol. 15: 429–435.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. Schopler E.,
    2. Reichler R. J.,
    3. DeVellis R. F.,
    4. Daly K.
    . 1980. Toward objective classification of childhood autism: childhood autism rating scale (CARS). J. Autism Dev. Disord. 10: 91–103.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. Smith R. A.,
    2. Farnworth H.,
    3. Wright B.,
    4. Allgar V.
    . 2009. Are there more bowel symptoms in children with autism compared to normal children and children with other developmental and neurological disorders? A case control study. Autism 13: 343–355.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Song Y.,
    2. Liu C.,
    3. Finegold S. M.
    . 2004. Real-time PCR quantitation of clostridia in feces of autistic children. Appl. Environ. Microbiol. 70: 6459–6465.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Vandesompele J.,
    2. et al
    . 2002. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3: RESEARCH0034.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Walker A. W.,
    2. Duncan S. H.,
    3. McWilliam Leitch E. C.,
    4. Child M. W.,
    5. Flint H. J.
    . 2005. pH and peptide supply can radically alter bacterial populations and short-chain fatty acid ratios within microbial communities from the human colon. Appl. Environ. Microbiol. 71: 3692–3700.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Wang L.,
    2. et al
    . 2010. Gut bacterial and fermentation profiles are altered in children with autism. J. Gastroenterol. Hepatol. 25(Suppl. 3): A116–A119.
    OpenUrlCrossRef
  26. 26.↵
    1. Wang L.,
    2. et al
    . 2009. Is urinary indolyl-3-acryloylglycine a biomarker for autism with gastrointestinal symptoms? Biomarkers 14: 596–603.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    1. Wexler H. M.
    2007. Bacteroides: the good, the bad, and the nitty-gritty. Clin. Microbiol. Rev. 20: 593–621.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Yap I. K.,
    2. et al
    . 2010. Urinary metabolic phenotyping differentiates children with autism, from their unaffected siblings and age-matched controls. J. Proteome Res. 9: 2996–3004.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Yu Z.,
    2. Morrison M.
    . 2004. Improved extraction of PCR-quality community DNA from digesta and fecal samples. Biotechniques 36: 808–812.
    OpenUrlPubMedWeb of Science
PreviousNext
Back to top
Download PDF
Citation Tools
Low Relative Abundances of the Mucolytic Bacterium Akkermansia muciniphila and Bifidobacterium spp. in Feces of Children with Autism
Lv Wang, Claus T. Christophersen, Michael J. Sorich, Jacobus P. Gerber, Manya T. Angley, Michael A. Conlon
Applied and Environmental Microbiology Sep 2011, 77 (18) 6718-6721; DOI: 10.1128/AEM.05212-11

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Applied and Environmental Microbiology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Low Relative Abundances of the Mucolytic Bacterium Akkermansia muciniphila and Bifidobacterium spp. in Feces of Children with Autism
(Your Name) has forwarded a page to you from Applied and Environmental Microbiology
(Your Name) thought you would be interested in this article in Applied and Environmental Microbiology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Low Relative Abundances of the Mucolytic Bacterium Akkermansia muciniphila and Bifidobacterium spp. in Feces of Children with Autism
Lv Wang, Claus T. Christophersen, Michael J. Sorich, Jacobus P. Gerber, Manya T. Angley, Michael A. Conlon
Applied and Environmental Microbiology Sep 2011, 77 (18) 6718-6721; DOI: 10.1128/AEM.05212-11
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About AEM
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AppEnvMicro

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

 

Print ISSN: 0099-2240; Online ISSN: 1098-5336